← Leaderboards
Narendra Wajapeyee
University Of Alabama At Birmingham
$10,700,120
Attributed
$13,044,308
Total exposure
14
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,044,308 · 14
By mechanism
R01$10,637,687 · 6
R21$2,003,275 · 6
R41$298,959 · 1
P30$104,387 · 1
Top collaborators
- Michael R Green4 shared
- Michelle Alice Kelliher4 shared
- Romi Gupta3 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Delia Smith West$10,703,923
- Renee A. Heffron$19,065,543
- Edward E Partridge$43,798,134
- Eric Hunter$78,178,241
- George Howard$21,516,429
Others in their field
Top investigators on “Pathway Interactions”
- David Heimbrook · Leidos Biomedical Research, Inc.$202,777,247
- Ralph Parchment · Leidos Biomedical Research, Inc.$146,974,543
- David R. Weir · University Of Michigan At Ann Arbor$129,316,139
- Daniel Ernest Ford · Johns Hopkins University$108,075,637
- David W Simpson · University Of Southern California$88,046,235
- Charles D. Blanke · Oregon Health And Science University$86,571,896
Research focus
Pathway InteractionsMouse ModelGrowthCessation Of LifeTumorMolecularEffective TherapyUnited StatesNew Therapeutic TargetOncogenicProteinsDrug TargetingCell Culture TechniquesNovel TherapeuticsNeoplasm MetastasisSamplingMediatingBaseTumor GrowthExperimental StudyGenesIn VivoAmericanMalignant Neoplasms
Grant awards (38)
Role of EZH2 as a Driver and Therapeutic Target of Hepatocellular Carcinoma$461,997
R01 · FY2025 · CA
Targeting melanoma promoting RNA modification pathway for melanoma therapy.$442,236
R01 · FY2025 · CA · contact PI
Deciphering and targeting a non-genetic driver pathway in hepatocellular carcinoma$386,648
R01 · FY2025 · CA · contact PI
A Novel Approach to Enhance Therapeutic Efficacy of Tarlatamab for Small Cell Lung Cancer Treatment$208,271
R21 · FY2025 · CA · contact PI
CRISPR and Humanized mice-based Discovery of a Novel Drug target for HCC Therapy$173,559
R21 · FY2025 · CA · contact PI
Role of EZH2 as a Driver and Therapeutic Target of Hepatocellular Carcinoma$438,898
R01 · FY2024 · CA
Deciphering and targeting a non-genetic driver pathway in hepatocellular carcinoma$403,041
R01 · FY2024 · CA · contact PI
CRISPR and Humanized mice-based Discovery of a Novel Drug target for HCC Therapy$208,271
R21 · FY2024 · CA · contact PI
02 - Experimental Therapeutics$104,387
P30 · FY2024 · CA · contact PI
Role of EZH2 as a Driver and Therapeutic Target of Hepatocellular Carcinoma$478,872
R01 · FY2023 · CA
Deciphering and targeting a non-genetic driver pathway in hepatocellular carcinoma$478,024
R01 · FY2023 · CA · contact PI
A Novel Druggable Epigenetic Vulnerability Pathway in HCC$569,273
R01 · FY2022 · CA
Deciphering and targeting a non-genetic driver pathway in hepatocellular carcinoma$478,024
R01 · FY2022 · CA · contact PI
A Novel Druggable Epigenetic Vulnerability Pathway in HCC$585,065
R01 · FY2021 · CA
Deciphering and targeting a non-genetic driver pathway in hepatocellular carcinoma$507,251
R01 · FY2021 · CA · contact PI
A Novel Druggable Epigenetic Vulnerability Pathway in HCC$590,486
R01 · FY2020 · CA
Nucleoporin NUP205-driven Novel Pathway in Melanoma Tumor Growth and Metastasis$339,694
R01 · FY2020 · CA · contact PI
A NOVEL DRUGGABLE GENETIC VULNERABILITY PATHWAY IN MELANOMA$339,694
R01 · FY2020 · CA · contact PI
A Novel Druggable Epigenetic Vulnerability Pathway in HCC$565,390
R01 · FY2019 · CA
Nucleoporin NUP205-driven Novel Pathway in Melanoma Tumor Growth and Metastasis$329,502
R01 · FY2019 · CA · contact PI
A NOVEL DRUGGABLE GENETIC VULNERABILITY PATHWAY IN MELANOMA$198,647
R01 · FY2019 · CA · contact PI
A DRUGGABLE CHROMATIN MODIFIER PATHWAY IN HCC$180,056
R21 · FY2019 · CA · contact PI
A NOVEL DRUGGABLE GENETIC VULNERABILITY PATHWAY IN MELANOMA$147,781
R01 · FY2019 · CA · contact PI
A Novel Druggable Epigenetic Vulnerability Pathway in HCC$599,752
R01 · FY2018 · CA
A NOVEL DRUGGABLE GENETIC VULNERABILITY PATHWAY IN MELANOMA$383,156
R01 · FY2018 · CA · contact PI
Nucleoporin NUP205-driven Novel Pathway in Melanoma Tumor Growth and Metastasis$383,156
R01 · FY2018 · CA · contact PI
A DRUGGABLE CHROMATIN MODIFIER PATHWAY IN HCC$115,103
R21 · FY2018 · CA · contact PI
A DRUGGABLE CHROMATIN MODIFIER PATHWAY IN HCC$103,485
R21 · FY2018 · CA · contact PI
A NOVEL DRUGGABLE GENETIC VULNERABILITY PATHWAY IN MELANOMA$383,156
R01 · FY2017 · CA · contact PI
Nucleoporin NUP205-driven Novel Pathway in Melanoma Tumor Growth and Metastasis$383,156
R01 · FY2017 · CA · contact PI
Nucleoporin NUP205-driven Novel Pathway in Melanoma Tumor Growth and Metastasis$382,966
R01 · FY2016 · CA · contact PI
A NOVEL DRUGGABLE GENETIC VULNERABILITY PATHWAY IN MELANOMA$381,822
R01 · FY2016 · CA · contact PI
Small molecule inhibitors targeting oncogenic drivers of hepatocellular carcinoma$298,959
R41 · FY2016 · CA · contact PI
ANOIKIS EFFECTORS AS DRIVERS OF METASTATIC MELANOMA$217,826
R21 · FY2016 · CA · contact PI
METABOLIC DRIVERS OF LUNG CANCER INITIATION, PROGRESSION AND THERAPY RESPONSE$217,283
R21 · FY2016 · CA · contact PI
Metabolic Drivers of Melanoma Initiation, Progression and Therapy Response$181,069
R21 · FY2016 · CA · contact PI
Metabolic Drivers of Melanoma Initiation, Progression and Therapy Response$217,283
R21 · FY2015 · CA · contact PI
METABOLIC DRIVERS OF LUNG CANCER INITIATION, PROGRESSION AND THERAPY RESPONSE$181,069
R21 · FY2015 · CA · contact PI